Versant-backed Gotham raises $54M series A

Versant Ventures unveiled a move into the RNA metabolism space with an investment in Gotham Therapeutics (New York, N.Y.). Versant co-led a $54 million series A round with Forbion Capital Partners and SR One.

Gotham is developing small molecules against epitranscriptomic mRNA readers, writers and erasers, based on research from co-founder Samie Jaffrey. Jaffrey is a professor of pharmacology at the Weill Medical College of Cornell University...